Benefit of cetuximab addition to a platinum–fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers

Vianney Bastit,Nicolas Bon-Mardion,Jean Michel Picquenot,Vinciane Rainville,Cristian Moldovan,Arnaud François,Agnès Loeb,S. Thureau,Dorel Manu,Fabrice Jardin,Jean-Paul Marie,Frédéric Di Fiore,Florian Clatot

Benefit of cetuximab addition to a platinum–fluorouracil-based chemotherapy according to KRAS-LCS6 variant in an unselected population of recurrent and/or metastatic head and neck cancers

2019

Vianney Bastit
Nicolas Bon-Mardion
Jean Michel Picquenot
Vinciane Rainville
Cristian Moldovan
Arnaud François
Agnès Loeb
S. Thureau
Dorel Manu
Fabrice Jardin
Jean-Paul Marie
Frédéric Di Fiore
Florian Clatot

Objectives To evaluate the benefit of cetuximab (Cx) addition to platinum-based and 5-fluorouracil chemotherapy (PFU) in unselected recurrent and/or metastatic head and neck cancer patients (R/MHNC) according to KRAS-LCS6 variant status.

Keywords:

Cetuximab
KRAS
Fluorouracil
Population
Head and neck cancer
Surgery
Oncology
Chemotherapy
Medicine
Internal medicine
Otorhinolaryngology
Performance status

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations